FactorPad
Build a Better Process

Stock Risk Measures for Esperion Therapeutics Inc

A quantitative factor review, as of September 30, 2020.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
by Paul Alan Davis, CFA
Updated: October 01, 2020
See how we arrive at an overall risk score of 67 for ESPR below.

/ factorpad.com / stocks / f22ctm.html


An ad-free and cookie-free webpage by FactorPad


ESPR Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Esperion Therapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how ESPR stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Biotechnology industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Identity

Sector and Industry

Share Data

Shares and Float

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f22ctm.html


ESPR stock risk
ESPERION THERAPEUTICS INC stock beta
ESPR risk report
ESPR f22ctm
ESPR risk analysis
ESPR volatility
ESPERION THERAPEUTICS INC credit risk
ESPR liquidity risk
ESPR leverage
ESPR valuation
ESPR systematic risk
ESPR specific risk
ESPERION THERAPEUTICS INC volatility
ESPR analysis
ESPR financial ratio

This is a new resource, spread the word, tell a friend